Technical Analysis for ATXI - Avenue Therapeutics, Inc.

Grade Last Price % Change Price Change
F 4.40 4.76% 0.20
ATXI closed up 4.76 percent on Wednesday, May 8, 2024, on 3.05 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: May 10
*** please verify all earnings dates ***
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Volume Surge Other 0.00%
Narrow Range Bar Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 4.76%
Shooting Star Candlestick Bearish 4.76%
Reversal New Lows Setup Bearish Swing Setup 4.76%
New Uptrend Bullish 4.76%

   Recent Intraday Alerts

Alert Time
Possible Inside Day about 17 hours ago
60 Minute Opening Range Breakout about 19 hours ago
3x Volume Pace about 19 hours ago
Up 10% about 19 hours ago
2x Volume Pace about 21 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Avenue Therapeutics, Inc. Description

Avenue Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in acquiring, licensing, developing and commercializing products principally for use in the acute or intensive care hospital setting. Its product candidate is intravenous (IV) Tramadol, an intravenous formulation of tramadol hydrochloride (HCl), for the management of moderate to moderately severe postoperative pain. Tramadol, a synthetic dual-acting opioid, is a centrally acting analgesic with weak opioid agonist properties. It also works via the inhibition of serotonin and noradrenaline re-uptake and blocking nociceptive impulses at the spinal level. Tramadol is also combined with acetaminophen (APAP) or nonsteroidal anti-inflammatory drugs (NSAIDS) in clinical practice. During the year ending December 31, 2016, the Company had completed a pharmacokinetics (PK) study for IV Tramadol in healthy volunteers.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Drugs Chemical Compounds Chloride Opioids Analgesics Amines Neurochemistry Hepatotoxins Pharmacokinetics Paracetamol Nonsteroidal Anti Inflammatory Drug

Is ATXI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 93.75
52 Week Low 4.04
Average Volume 67,406
200-Day Moving Average 27.95
50-Day Moving Average 10.07
20-Day Moving Average 7.44
10-Day Moving Average 5.19
Average True Range 1.17
RSI (14) 15.25
ADX 41.05
+DI 20.40
-DI 20.01
Chandelier Exit (Long, 3 ATRs) 8.13
Chandelier Exit (Short, 3 ATRs) 7.54
Upper Bollinger Bands 12.47
Lower Bollinger Band 2.41
Percent B (%b) 0.2
BandWidth 135.18
MACD Line -1.78
MACD Signal Line -1.51
MACD Histogram -0.2756
Fundamentals Value
Market Cap 164.14 Million
Num Shares 37.3 Million
EPS -2.62
Price-to-Earnings (P/E) Ratio -1.68
Price-to-Sales 0.00
Price-to-Book 2.17
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.26
Resistance 3 (R3) 5.27 4.99 5.11
Resistance 2 (R2) 4.99 4.78 4.99 5.06
Resistance 1 (R1) 4.70 4.64 4.85 4.69 5.02
Pivot Point 4.42 4.42 4.50 4.42 4.42
Support 1 (S1) 4.13 4.21 4.28 4.12 3.78
Support 2 (S2) 3.85 4.07 3.85 3.74
Support 3 (S3) 3.56 3.85 3.69
Support 4 (S4) 3.55